Pfizer Reports Results of Xeljanz XR (tofacitinib) in the P-IIIB/IV ORAL Shift Study for Moderate to Severe Rheumatoid Arthritis #EULAR2019
Shots:
- The P-IIIB/IV study results involve assessing of Xeljanz XR (11 mg- qd) as monothx. followed by MTX withdrawal vs Xeljanz XR + MTX in 530 patients in ratio (1:1) with moderate to severe rheumatoid arthritis
- The P-IIIB/IV study results: @24-48 wks.- LS mean changes in Disease Activity Score (DAS28-4 [ESR]) (0.33 vs 0.03); AEs (40.5% vs 41.0%); SAEs (3.8% vs 1.9%)- will be presented at EULAR 2019
- Xeljanz XR is JAK inhibitor and has received approval in 130+ countries including the US for moderately to severely active rheumatoid arthritis- ulcerative colitis and psoriatic arthritis
Ref: Pfizer | Image: Fortune
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com